Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1636
This examiner grants 39% of resolved cases
Douglas Charles Ryan is an examiner in Tech Center 1600 and Art Unit 1635. The examiner has 74 resolved cases. The allowance rate for these matters is 39.2%. This metric provides a baseline for the likelihood of securing a patent grant during prosecution. The 39.2% rate is a primary data point for evaluating the probability of success in this specific Art Unit.
The interview lift is 47.6%. This value measures the increase in the probability of allowance following an interview. A lift of 47.6% indicates that engaging in a direct dialogue with the examiner can be a productive strategy. Practitioners should weigh this 47.6% figure when deciding whether to request a formal interview for their 74 resolved cases.
The median days to allowance is 1164. This figure represents the typical time span from filing to the issuance of a patent. A median of 1164 days informs the scheduling and budget expectations for applicants. This 1164 days duration is a factor in the overall prosecution timeline.
In Tech Center 1600, the examiner's 39.2% allowance rate and 74 resolved cases define the current landscape. The interview lift serves as a tool for navigating the prosecution process toward a grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18692438 | AAVRH74 PARTICLES FOR GENE THERAPY OF MUSCLE DISEASE | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18026389 | COMPOSITIONS AND METHODS FOR MODULATION OF BACTERIAL GENE EXPRESSION | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18578052 | POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIA | Non-Final OA | ModernaTX, Inc. |
| 18012094 | LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE | Final Rejection | ModernaTX, Inc. |
| 18417305 | SYNTHETIC YEAST CELLS AND METHODS OF MAKING AND USING THE SAME | Final Rejection | Wisconsin Alumni Research Foundation |
| 18554627 | GENE THERAPY FOR NEUROPROTECTION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17630875 | SYNTHETIC IMMUNE CELLS AND METHODS OF USE THEREOF | Final Rejection | The Regents of the University of California |
| 17544527 | Screening for Inhibitors of Prostaglandin E Synthase 3 Useful for Treatment of Prostate Cancer | Non-Final OA | The Regents of the University of California |
| 18005311 | Targeted RNA cleavage with dCas13-RNase Fusion Proteins | Final Rejection | University of Rochester |
| 17124999 | MULTIPLEXED IN VIVO DISEASE SENSING WITH NUCLEIC ACID-BARCODED REPORTERS | Final Rejection | Massachusetts Institute of Technology |
| 17097484 | OPTOGENETIC CIRCUITS FOR CONTROLLING CHEMICAL AND PROTEIN PRODUCTION IN ESCHERICHIA COLI | Non-Final OA | THE TRUSTEES OF PRINCETON UNIVERSITY |
| 17493293 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 18394091 | ANTIGEN-BINDING MOLECULE AND COMBINATION | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 17417822 | MUTATED tRNA FOR CODON EXPANSION | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18294722 | EPIGENETIC MODULATORS FOR TISSUE REPROGRAMMING | Non-Final OA | THE TRUSTEES OF INDIANA UNIVERSITY |
| 17362038 | Method for selecting cells based on CRISPR/Cas-mediated integration of a detectable tag to a target protein | Final Rejection | Hoffmann-La Roche Inc. |
| 17599616 | UNIVERSAL DNA ASSEMBLY | Non-Final OA | Oxford University Innovation Limited |
| 17413434 | Methods For Increasing The Productivity Of A Filamentous Fungal Cell In The Production Of A Polypeptide | Non-Final OA | Novozymes A/S |
| 17602411 | A Ribozyme Comprising a Target-Binding Domain | Final Rejection | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH |
| 16826010 | ACTIVITY-DEPENDENT GENE PAIRS AS THERAPEUTIC TARGETS AND METHODS AND DEVICES TO IDENTIFY THE SAME | Non-Final OA | Wayne State University |
| 18609899 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RARE DISEASES | Non-Final OA | Sangamo Therapeutics, Inc. |
| 18042193 | A METHOD FOR THE ISOLATION OF DOUBLE-STRAND BREAKS | Final Rejection | University College Cardiff Consultants Ltd |
| 17615513 | IMPROVED METHODS AND COMPOSITIONS FOR INCREASED DOUBLE STRANDED RNA PRODUCTION | Final Rejection | RNAISSANCE AG LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy